MBX Biosciences, Inc. · 2 weeks ago
Vice President, Biometrics
Greater Boston
Full-time
Hybrid
Director/Executive
15+ years expMBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on novel precision peptide therapies. The Vice President of Biometrics will lead the biometrics function, ensuring the integrity and quality of clinical trial data while driving innovative data strategies.
BiotechnologyHealth CareTherapeutics
Responsibilities
Lead and build the Biometrics function, including biostatistics, programming, and data management, ensuring high-quality deliverables across all clinical programs
Oversee design and implementation of statistical methodologies for clinical trials
Ensure high quality and compliant biometric deliverables
Collaborate with cross-functional teams on protocols, statistical analysis plans, and data processes
Execute statistical analysis plans, ensuring statistical integrity and data consistency
Establish SOPs and best practices for innovative biometric strategies
Establish and maintain vendor partnerships ensuring quality and timely delivery of outsources biometrics activities
Support regulatory submissions and represent the company in agency interactions
Champion continuous improvement to enhance processes, systems, and compliance standards across the Biometrics function and organization
Other responsibilities as assigned
Qualification
Required
Advanced degree (PhD or MS) in Biostatistics or related field
15+ years of biometrics experience within the biotech or pharmaceutical field
Proven track record of leading, building, and managing teams
Deep knowledge of clinical trial design, regulator requirements, and statistical software
Excellent problem-solving skills, strategic thinking, and ability to work in a fast-paced, collaborative environment
Outstanding scientific leadership and collaboration skills
Outstanding interpersonal skills, self-awareness, and ability to manage team dynamics
Company
MBX Biosciences, Inc.
MBX Biosciences, Inc. is a clinical stage biopharmaceutical company pioneering investigational Precision Endocrine Peptides (PEPs™).
11-50 employees
Funding
Current Stage
Public CompanyTotal Funding
$238.4MKey Investors
Deep Track CapitalWellington ManagementFrazier Healthcare Partners
2024-09-13IPO
2024-08-05Series C· $63.5M
2022-11-14Series B· $115M
Leadership Team
P. Kent Hawryluk
President & CEO
Michelle Graham
Chief Human Resources Officer
Recent News
Longevity.Technology
2026-01-16
MarketScreener
2025-12-22
Company data provided by crunchbase